|Day Low/High||188.92 / 191.25|
|52 Wk Low/High||184.50 / 317.48|
Stocks hold mixed on Friday after U.S. jobs gains in November solidify the chances of a December rate hike.
U.S. stocks were mixed Friday, despite a better than expected jobs report.
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer
Stock futures hold lower on Friday after U.S. job gains in November come in around forecasts.
Watch Jim Cramer, Nelson Peltz, Brent Saunders and more give you their best ideas on the state of the M&A economy.
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
Will investors want to wait 12 to 18 months to see Allergan's deals pay dividends?
Market should still be able to breathe once central-bank prop is removed.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.
The markets reach record highs in a short week as oil and a potential rate hike get much of the attention.
'Milestone payments' could boost deal's $125 million announced price.
Positive results mean a lot for HD and CRBP, says Jim Cramer.
The number and magnitude of earnings surprises has a big impact on the markets, says Jim Cramer.
- Acquisition Adds Development Programs Focused on Enabling Improved Treatment in Alzheimer's disease -
We'll buy more Allergan shares, with the risk-reward skewed heavily to the upside.
Previously this month activist Carl Icahn has unloaded most of the stake he built up earlier in the year.
-- An Ab Interno Approach to Reduce Intraocular Pressure in Patients with Refractory Glaucoma -
Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.
Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
In highlights from this week's trading diary and posts, Kass tells us about how to say no to closed-end muni bond funds and why Cara Therapeutics is on a run.
The rally keeps rolling, with financials showing continued strength. Two names were added to the portfolio, including a returnee.